Latest news with #DavidMiller
Yahoo
7 hours ago
- Business
- Yahoo
Simulations Plus Releases ADMET Predictor® 13
Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment RESEARCH TRIANGLE PARK, N.C., June 05, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. "ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space," said David Miller, Vice President of Cheminformatics of Simulations Plus. "Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world." Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
7 hours ago
- Business
- Business Wire
Simulations Plus Releases ADMET Predictor® 13
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. 'ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space,' said David Miller, Vice President of Cheminformatics of Simulations Plus. 'Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world.' Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
Yahoo
a day ago
- Politics
- Yahoo
Professor prosecuted over tweets calling for Jews to be ‘de-Zionised'
An academic is facing a private prosecution over social media posts calling for Jews to be 'de-Zionised'. The Campaign Against Antisemitism (CAA) has brought three charges against Prof David Miller over posts on X. They allege that he used a public communications network to send messages of a menacing character, contrary to the Communications Act 2003. Prof Miller was previously found to have been unfairly and wrongfully dismissed by the University of Bristol in October 2021 after making comments criticising Israel. The CAA said the first message was posted on Nov 8 last year in relation to a discussion on violence in Amsterdam after a football match involving an Israeli team. It said: 'Last night's response by the brave Muslim communities of Amsterdam was necessary, but extremely measured and not at all proportional to the genocidal violence unleashed by Zionist terrorists on the Levant, on Muslims worldwide, or indeed in the provocations that preceded the measured response. Future incidents will likely involve a more proportional response. 'As well as being unwelcoming to Zionist colonists coming from Occupied Palestine, Europe must be unviable as a base for Zionist terror by Jewish supremacists who have infiltrated and are camouflaged among us. 'Zionist terrorist entryists must be expunged from European institutions, whether political parties, media, think tanks or elsewhere. Again, either institutions take the lead and conduct this work in orderly fashion with advice from experts on Zionist subversion, or the people will take care of it for them.' The first hearing is set to take place at Westminster magistrates' court on July 2, HM Courts & Tribunals Service confirmed. Prof Miller is alleged to have sent another message on March 20, saying: 'Every genuinely anti-Zionist Jew can count on being kept safe by the movement, when the time comes. Every Zionist Jew must be held accountable and de-Zionised. #DismantleZionism.' On March 24, he is said to have made another post saying: 'Protests are not enough. Listen to our brothers and sisters in Gaza. 'Those who are interested in ending this genocide must begin by targeting those responsible near them: the entire Zionist movement globally must live in fear of accountability until it is dismantled and its ideology eradicated. And let's be clear, there are Zionists everywhere. In every town and city. Find out where they are. #DismantleZionism.' He successfully claimed at an employment tribunal last year that he experienced discrimination based on his anti-Zionist belief. The CAA describes itself as an organisation of volunteers that works to 'expose and counter antisemitism through education and zero-tolerance enforcement of the law'. Prof Miller has been approached for comment. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Telegraph
a day ago
- General
- Telegraph
Professor prosecuted over tweets calling for Jews to be ‘de-Zionised'
An academic is facing a private prosecution over social media posts calling for Jews to be 'de-Zionised'. The Campaign Against Antisemitism (CAA) has brought three charges against Prof David Miller over posts on X. They allege that he used a public communications network to send messages of a menacing character, contrary to the Communications Act 2003. Prof Miller was previously found to have been unfairly and wrongfully dismissed by the University of Bristol in October 2021 after making comments criticising Israel. 'Zionist subversion' The CAA said the first message was posted on Nov 8 last year in relation to a discussion on violence in Amsterdam after a football match involving an Israeli team. It said: 'Last night's response by the brave Muslim communities of Amsterdam was necessary, but extremely measured and not at all proportional to the genocidal violence unleashed by Zionist terrorists on the Levant, on Muslims worldwide, or indeed in the provocations that preceded the measured response. Future incidents will likely involve a more proportional response. 'As well as being unwelcoming to Zionist colonists coming from Occupied Palestine, Europe must be unviable as a base for Zionist terror by Jewish supremacists who have infiltrated and are camouflaged among us. 'Zionist terrorist entryists must be expunged from European institutions, whether political parties, media, think tanks or elsewhere. Again, either institutions take the lead and conduct this work in orderly fashion with advice from experts on Zionist subversion, or the people will take care of it for them.' '#DismantleZionism' The first hearing is set to take place at Westminster magistrates' court on July 2, HM Courts & Tribunals Service confirmed. Prof Miller is alleged to have sent another message on March 20, saying: 'Every genuinely anti-Zionist Jew can count on being kept safe by the movement, when the time comes. Every Zionist Jew must be held accountable and de-Zionised. #DismantleZionism.' On March 24, he is said to have made another post saying: 'Protests are not enough. Listen to our brothers and sisters in Gaza. 'Those who are interested in ending this genocide must begin by targeting those responsible near them: the entire Zionist movement globally must live in fear of accountability until it is dismantled and its ideology eradicated. And let's be clear, there are Zionists everywhere. In every town and city. Find out where they are. #DismantleZionism.' He successfully claimed at an employment tribunal last year that he experienced discrimination based on his anti-Zionist belief. The CAA describes itself as an organisation of volunteers that works to 'expose and counter antisemitism through education and zero-tolerance enforcement of the law'.
The Independent
a day ago
- General
- The Independent
Academic faces private prosecution over posts on X
An academic is facing a private prosecution by the Campaign Against Antisemitism (CAA) charity over posts on social media. Three charges have been brought by the CAA alleging that Professor David Miller used a public communications network to send messages of a menacing character, contrary to section 127 of the Communications Act 2003. The first hearing is set to take place at Westminster Magistrates' Court on July 2, HM Courts & Tribunals Service confirmed. The case relates to posts on X, which Mr Miller is alleged to have published in recent months. The CAA said the first message was posted on November 8 last year in relation to a discussion on violence in Amsterdam after a football match involving an Israeli team. He is alleged to have sent another message on March 20, saying: 'Every genuinely anti-Zionist Jew can count on being kept safe by the movement, when the time comes. Every Zionist Jew must be held accountable and de-Zionised. #DismantleZionism.' On March 24, he is said to have posted another tweet saying: 'Protests are not enough. Listen to our brothers and sisters in Gaza. Those who are interested in ending this genocide must begin by targeting those responsible near them: the entire Zionist movement globally must live in fear of accountability until it is dismantled and its ideology eradicated. And let's be clear, there are Zionists everywhere. In every town and city. Find out where they are. #DismantleZionism.' Mr Miller was previously found to have been unfairly and wrongfully dismissed by the University of Bristol in October 2021 after making comments criticising Israel. He successfully claimed at an employment tribunal last year that he experienced discrimination based on his anti-Zionist belief. The CAA describes itself as an organisation of volunteers which works to 'expose and counter antisemitism through education and zero-tolerance enforcement of the law'.
